Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study).

Fiche publication

Date publication

octobre 2024

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine

Tous les auteurs :
Laharie D, Bouhnik Y, Vuitton L, Biron A, Pierron G, Brault Y, Assing M, Bouzidi A, Amiot A, Nancey S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39448029

Résumé

ReFLECT was a French, prospective, multicenter, observational cohort study evaluating the effectiveness and safety of the infliximab (IFX) biosimilar CT-P13 in a real-world setting. Here, we describe the results for adults with inflammatory bowel disease (IBD).